World Health Organization site
Skip Navigation Links

Main
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 17 October 2012
Main ID:  NCT00713739
Date of registration: 07/07/2008
Primary sponsor: United States Naval Medical Center, San Diego
Public title: Alfuzosin for Medical Expulsion Therapy of Ureteral Stones MET
Scientific title: Evaluation of Alfuzosin as Medical Expulsion Therapy for Ureteral Stones
Date of first enrolment: January 2008
Target sample size: 240
Recruitment status: Recruiting
URL:  http://clinicaltrials.gov/show/NCT00713739
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment  
Countries of recruitment
United States
Contacts
Name:   Brian K Auge, M.D.
Address: 
Telephone: 619-532-7200
Email:
Affiliation: 
Name:   Brian K. Auge, M.D.
Address: 
Telephone: 619-532-7200
Email:
Affiliation: 
Name:   Brian K. Auge, M.D.
Address: 
Telephone:
Email:
Affiliation:  NMCSD
Name:   Sean P. Stroup, M.D.
Address: 
Telephone:
Email:
Affiliation:  NMCSD
Key inclusion & exclusion criteria

Inclusion Criteria:

- Age >/= 18 years

- Single ureteral stone < 1 cm in greatest dimension

Exclusion Criteria:

- Age < 18 years

- Active unstable angina

- History of or active postural hypotension (>20 mmHg drop in orthostatic SBP)

- Allergy to alpha-blockers

- Acute or Chronic Renal Failure as demonstrated by a serum creatinine of > 1.4 mg/dl

- Urinary tract infection

- Multiple ureteral stones

- Current uncontrolled diabetes

- Alpha-blocker therapy within 30 days for any reason

- Current pregnancy or lactation

- Patient desire for immediate stone removal



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Kidney Stones
Intervention(s)
Drug: Alfuzosin
Drug: doxazosin
Drug: nifedipine
Drug: prazosin
Primary Outcome(s)
The primary measures are percent of stones passed and rates of occurrence of various side effects (categorical variables), and time to pass, pain scale, and amount of pain medication taken (continuous variables). [Time Frame: Period of stone passage (30 days)]
Secondary Outcome(s)
Secondary ID(s)
NMCSD CID 06-050
Office of Naval Research FY08
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.1 - Version history